Weyer-Czernilofsky, Ulrike
Boehringer Ingelheim (Austria)
3 papers on CoChatORCID 0000-0001-8869-581X
Most cited papers
- Verified
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
Hirt, U. A., Waizenegger, I. C., Schweifer, N., Haslinger, C., Gerlach, D., Braunger, J., Weyer-Czernilofsky, U., Stadtmüller, H., Sapountzis, I., Bader, G., et al. (2018) · Oncogenesis
Cell Adhesion Molecules ResearchCancer Cells and Metastasis
Cited by 63
- Verified
BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models
Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H. (2023) · Neuro-Oncology
Cancer-related Molecular PathwaysGlioma Diagnosis and Treatment
Cited by 34
- Verified
Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules
Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., et al. (2024) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysCancer Mechanisms and Therapy
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free